Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population

British Journal of Clinical Pharmacology

Volumn 42, Issue 6, 1996, Pages 771-773

  Basci, N E ^a   Bozkurt, A ^a   Kortunay, S ^a   Isimer, A ^b   Sayal, A ^b   Kayaalp, S O ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

mephenytoin; oxidation polymorphisms; proguanil; Turkish population

Indexed keywords

CYCLOGUANIL; DRUG METABOLITE; MEPHENYTOIN; PROGUANIL;

ADULT; ARTICLE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; OXIDATION; POPULATION; PRIORITY JOURNAL; TURKEY (REPUBLIC);

EID: 0029903784     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.00500.x     Document Type: Article

References (17)

1. Hawking F, Perry WLM. Activation of paludrine. Br J Pharmacol 1948; 3: 320-325.
2. Carrington HC, Crowther AF, Davey DG, Levi AA, Rose FL. Metabolites of paludrin with high antimalarial activity. Nature 1951; 168: 184-189.
3. Worsley DE. Plasma paludrine levels-Far East 1970. J Army Med Corps 1975; 131: 148-151.
4. Kelly JA, Fletcher KA. High-performance liquid chromatographic method for the determination of proguanil and cycloguanil in biological fluids. J Chromatogr 1986; 381: 464-471.
5. Ward SA, Watkins WM, Mberu E, et al. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol 1989; 27: 781-787.
6. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 1990; 30: 593-598.
7. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism-a panel study. Br J Clin Pharmacol 1991; 31: 689-692.
8. Wrington SA, Stevens JC, Becker GW, Vanda-Branden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993; 306, 240-245.
9. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Vernose ME. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 1994; 37: 413-420.
10. Brosen K, Skjelbo E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993; 36: 105-108.
11. Edstein MD, Shanks GD, Teja-Isavadharm P, Reickmann KH, Webster HK. Oxidative activation of proguanil and dapsone acetylation in Thai soldiers. Br J Clin Pharmacol 1994; 37: 67-70.
12. Wanwilmolruk S, Thou MR, Woods DJ. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population. Br J Clin Pharmacol 1995; 40: 166-169.
13. Watkins WM, Mberu EK, Nevill CG, Ward SA, Breckenridge AM, Koech DK. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg 1990; 84: 492-495.
14. Skjelbo E, Mutabingwa TK, Bygbjerg I, Nielsen KK, Gram LF, Brosen K. Proguanil metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 1996; 59: 304-311.
15. Sanz EJ, Villén T, Alm C, Bertillsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989; 45: 495-499.
16. Funck-Brentano C, Bosco O, Jacqz-Aigrain E, Keudjian A, Jaillon P. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. Clin Pharmacol Ther 1992; 51: 507-512.
17. Partovian C, Jacqz-Aigrain E, Keudjian A, Jaillon P, Funck-Brentano C. Comparison of chloroguanid and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans. Clin Pharmacol Ther 1995; 58: 257-263.